Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"

被引：8
|
作者：
Webster, Christopher J. [1 ]
Woollett, Gillian R. [2 ]
机构：
[1] BioApprovals, Acton, MA USA
[2] Avalere Hlth Inc, FDA Strategy & Regulatory Policy, Washington, DC 20036 USA
来源：
BIODRUGS | 2018年 / 32卷 / 05期
关键词：
D O I：
10.1007/s40259-018-0297-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：519 / 521
页数：3
相关论文
共 50 条
  • [31] ON THE DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS WITH MULTIPLE END-POINTS - COMMENT
    LEHMACHER, W
    WASSNER, G
    REITMEIR, P
    BIOMETRICS, 1994, 50 (02) : 581 - 583
  • [32] The role of clinical nonfatal end points in cardiovascular Phase II/III clinical trials
    O'Connor, CM
    Gattis, WA
    Ryan, TJ
    AMERICAN HEART JOURNAL, 2000, 139 (04) : S143 - S154
  • [33] Biosimilars in the EU: Nonclinical and Early Clinical Development
    Voisin, Emmanuelle
    Uguen, David
    Deneux, Marie
    DRUG INFORMATION JOURNAL, 2010, 44 (06): : 741 - 743
  • [34] Clinical development of biologicals and biosimilars - safety concerns
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (06) : 567 - 569
  • [35] Phase 3 clinical development
    不详
    BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT, 2002, : 29 - 33
  • [36] Clinical Trials on Sarcopenia: Methodological Issues Regarding Phase 3 Trials
    van Kan, Gabor Abellan
    Chumlea, Wm Cameron
    Gillette-Guyonet, Sophie
    Houles, Mathieu
    Dupuy, Charlotte
    Rolland, Yves
    Vellas, Bruno
    CLINICS IN GERIATRIC MEDICINE, 2011, 27 (03) : 471 - +
  • [37] Clinical Trials Nursing roles during the approval process and pharmacovigilance of biosimilars
    Sugay, Jazel Dolores
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2018, 22 (05) : 27 - 32
  • [38] Biosimilars for the Treatment of Psoriasis A Systematic Review of Clinical Trials and Observational Studies
    Phan, Duc Binh
    Elyoussfi, Sarah
    Stevenson, Michael
    Lunt, Mark
    Warren, Richard B. B.
    Yiu, Zenas Z. N.
    JAMA DERMATOLOGY, 2023, 159 (07) : 763 - 771
  • [39] Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials
    Hung, Anna
    Schneider, Monika
    Lopez, Marianne Hamilton
    McClellan, Mark
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (07): : 888 - 900
  • [40] Clinical data from Phase 3 trials in Pramlintide
    不详
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 1999, 15 (02) : 157 - 157
12345